ON4 Stock Overview
Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Ono Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥12.60 |
| 52 Week High | JP¥18.80 |
| 52 Week Low | JP¥12.60 |
| Beta | 0.18 |
| 1 Month Change | -10.00% |
| 3 Month Change | n/a |
| 1 Year Change | -26.74% |
| 3 Year Change | -41.67% |
| 5 Year Change | -19.28% |
| Change since IPO | 71.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| ON4 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -10.0% | 3.2% | 1.7% |
| 1Y | -26.7% | -28.2% | 2.3% |
Return vs Industry: ON4 exceeded the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: ON4 underperformed the German Market which returned 2.3% over the past year.
Price Volatility
| ON4 volatility | |
|---|---|
| ON4 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: ON4 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ON4's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1717 | 3,761 | Gyo Sagara | www.ono-pharma.com |
Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer’s disease; Ongentys tablets for Parkinson’s disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis.
Ono Pharmaceutical Co., Ltd. Fundamentals Summary
| ON4 fundamental statistics | |
|---|---|
| Market cap | €6.39b |
| Earnings (TTM) | €764.36m |
| Revenue (TTM) | €2.98b |
8.4x
P/E Ratio2.1x
P/S RatioIs ON4 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ON4 income statement (TTM) | |
|---|---|
| Revenue | JP¥498.07b |
| Cost of Revenue | JP¥121.74b |
| Gross Profit | JP¥376.33b |
| Other Expenses | JP¥248.72b |
| Earnings | JP¥127.61b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 09, 2024
| Earnings per share (EPS) | 271.68 |
| Gross Margin | 75.56% |
| Net Profit Margin | 25.62% |
| Debt/Equity Ratio | 0% |
How did ON4 perform over the long term?
See historical performance and comparison